To evaluate the effects of digoxin in patients with the newly described phenotype of heart failure (HF) and mid-range ejection fraction (HFmrEF) 
Introduction
In 2016, the European Society of Cardiology (ESC) guidelines on heart failure (HF) introduced the term HF with mid-range ejection fraction (HFmrEF) to describe patients with a left ventricular ejection fraction (LVEF) in the range of 40-49%. of patients enrolled in the majority of previous clinical trials] nor a near-normal or normal ('preserved') LVEF (i.e. ≥50%, here after referred to as HFpEF). Patients with a LVEF 40-49% were either the minority of those enrolled in prior trials, or were excluded from previous trials, and represent a 'grey area' with respect to pathophysiological understanding and treatment choices. 2 -4 The ESC guidelines suggested that patients with HFmrEF may represent an intermediate phenotype, likely characterised by the presence of mild left ventricular systolic dysfunction. 1 One way to test the hypothesis is to examine the effect of treatments that are known to be beneficial in HFrEF in patients with HFmrEF. Perhaps the prototypical agent of this type is digoxin. As an inotrope, digoxin might be expected to be of benefit in systolic dysfunction but not in diastolic dysfunction. The Digitalis Investigation Group (DIG) trial, which enrolled patients with a LVEF ranging between 3% and 85%, offered the opportunity to compare the effect of digoxin in HFrEF, HFmrEF and HFpEF. 5, 6 We have carried out a retrospective analysis of the effect of digoxin in patients with HFmrEF in DIG.
Methods

DIG inclusion and exclusion criteria
The rationale, design and results of DIG have been published. 5, 6 Patients were randomised at 302 clinical centres in the United States and Canada. The study was approved by the ethics committee at each participating centre and all patients gave written informed consent. Patients were eligible for the main trial if they had HF and a LVEF of ≤45% and were in normal sinus rhythm (6800 patients). 5 Patients with HF and a LVEF of >45% were enrolled in an ancillary trial conducted in parallel to the main trial (988 patients). 6 The diagnosis of HF was based on current or previous symptoms (limitation of activity, fatigue, and dyspnoea or orthopnoea), signs (oedema, elevated jugular venous pressure, rales, or a third heart sound/gallop rhythm), or radiologic evidence of pulmonary congestion. Exclusion criteria included a serum potassium concentration < 3.2 mmol/L or >5.5 mmol/L and significant renal insufficiency (creatinine >3.0 mg/dL) or severe liver disease. Investigators were strongly encouraged to give study patients an angiotensin-converting enzyme inhibitor. 5, 6 Study drug randomisation and dosing, and trial outcomes Patients were randomly assigned to receive digoxin or placebo and follow-up visits took place at 4 and 16 weeks after randomisation and every 4 months thereafter. 5, 6 The primary outcome in DIG was death from any cause. The trial secondary outcomes included death from cardiovascular causes, death from worsening HF, and hospitalisation for worsening HF. 5, 6 For the purposes of the present study, we used the composite of cardiovascular death or HF hospitalisation as the primary outcome, reflecting the most commonly used endpoint in contemporary HF trials.
Left ventricular ejection fraction categories
For the purposes of comparing the clinical characteristics of and outcomes in HFrEF, HFmrEF and HFpEF, patients were divided into three mutually exclusive LVEF categories: <40% (HFrEF), 40-49% (HFmrEF), and ≥50% (HFpEF). 1
Statistical analysis
We had full access to anonymised individual-patient data via the Virtual International Cardiovascular and Cognitive Trials Archive (VICCTA). 7, 8 . We examined the effect of randomised treatment on the following major clinical outcomes: the composite of cardiovascular death or HF hospitalisation (primary endpoint for the present study); the composite of HF death or HF hospitalisation (a pre-specified composite outcome in DIG and considered to be the outcome most sensitive to the effect of digoxin); the components of these composites; and all-cause death (the pre-specified primary endpoint in DIG). Comparison of clinical outcomes among treatment groups was performed using Kaplan-Meier estimates, with log-rank test, and a supportive Cox proportional-hazards regression model to calculate hazard ratios (HR) and 95% confidence intervals (CI). The reported HRs were adjusted for age and sex. The interaction between LVEF category and the effect of treatment was also examined for each clinical outcome. The analyses were undertaken using SAS version 9.3 (SAS Institute, Inc., Cary, NC, USA).
The interaction between LVEF as a continuous variable and the effect of treatment on the composite outcome was also examined and graphically displayed using fractional polynomial function. 9 The rates of the composite outcome across LVEF was examined using the restricted cubic spline method. The fractional polynomial and restricted cubic spline analyses were undertaken using the mfpi and incspline commands, respectively, in STATA version 14 (College Station, TX, USA).
Results
There were 7788 patients with a LVEF available for analysis in the public use version of the DIG database. The median LVEF was 30% (IQR 23-39%). Of the 7788 patients analysed, 5874 (75%) had HFrEF, 1195 (15%) had HFmrEF and 719 had HFpEF (9%).
Baseline characteristics
The baseline characteristics of the patients in each LVEF category are shown in 
Symptoms and signs of heart failure
With two exceptions, the prevalence of all symptoms and signs was lowest in patients with HFmrEF, compared to the other two LVEF categories ( Table 2 ). The exceptions were dyspnoea at rest or on exertion, which had the same prevalence in HFmrEF and HFrEF (95.2%), compared with HFpEF (96.9%) and the frequency of a third All continuous values are given in mean ± standard deviation unless stated otherwise. ACE, angiotensin-converting enzyme; BMI, body mass index; BP, blood pressure; CHF, chronic heart failure; HFmrEF, heart failure with mid-range ejection fraction; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; LVEF, left ventricular ejection fraction; NYHA, New York Heart Association. * The clinical signs or symptoms studied included rales, elevated jugular venous pressure, peripheral oedema, dyspnoea at rest or on exertion, orthopnoea, limitation of activity, S 3 gallop and radiological evidence of pulmonary congestion.
heart sound gallop rhythm, which was considerably less common in both patients with HFmrEF (37.9%) and HFpEF (33.0%) than in those with HFrEF (51.9%). Cardiothoracic ratio was also lower in patients with HFmrEF (0.51) and HFpEF (0.52) than in individuals with HFrEF (0.53).
Clinical outcomes
Comparison of the primary composite outcome in the placebo group across LVEF categories showed a significantly higher rate in the HFrEF patients compared with the other two groups ( Table 3 , Figures 1 and 2) . Figure 1 ). The same was true for each component of the composite, i.e. cardiovascular death and HF hospitalisation separately and the pre-specified DIG composite of HF death or HF hospitalisation (and its components). A similar pattern was observed for all-cause death ( Table 3) . Overall, 86.0% of deaths in patients with HFrEF were due to a cardiovascular cause; this proportion was 74.4% in patients with HFmrEF and 78.4% in patients with HFpEF.
The restricted cubic spline analysis suggested a LVEF inflection point of around 35%, below which the rate of the primary composite outcome increased linearly (Figure 2) . HFmrEF, heart failure with mid-range ejection fraction; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction. Rate per 100 patient-years. All reported HR were adjusted for age and sex. CI, confidence interval; CV, cardiovascular; HF, heart failure; HFmrEF, heart failure with mid-range ejection fraction; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; HR, hazard ratio; LVEF, left ventricular ejection fraction. * P-value for interaction between treatment groups with ejection fraction categories.
Effect of digoxin
Digoxin reduced the risk of the primary composite outcome in patients with HFrEF, an effect mainly due to a significant reduction in HF hospitalisation: the digoxin/placebo HR for HF hospitalisation in patients with HFrEF was 0.71 (95% CI 0.65-0.77) ( The fractional polynomial analysis showed a clear benefit of digoxin on the primary composite endpoint up to a LVEF of around 35%, with a smaller, if any, effect above that value although the interaction P-value examining effect of digoxin according to LVEF was 0.604 ( Figure 3) .
Discussion
Prior studies of ambulatory cohorts have shown that approxi- Heart Failure: Assessment of Mortality and morbidity (CHARM), 15% of 9134 patients in the ESC Heart Failure Long-Term Registry and 13% of a Spanish cohort of 3446 patients. 10 -13 However, the largest study (n = 41 446) of ambulatory patients from Sweden found that 21.5% had HFmrEF. 14 It is not clear why the Swedish cohort had a higher prevalence than the other studies, especially the ESC registry, although our patients all were in sinus rhythm whereas the Swedish Registry included many patients with atrial fibrillation (65%, 60%, and 53% in HFpEF, HFmrEF and HFrEF, respectively). We found that patients with HFmrEF resembled patients with HFrEF, more than those with HFpEF, with respect to age, sex and aetiology (particularly ischaemic aetiology). On the other hand, blood pressure and the prevalence of hypertension were higher in patients with HFmrEF than in patients with HFrEF, although not as high as in HFpEF. This pattern is consistent with the prior studies alluded to earlier.
Despite the similarities to HFrEF mentioned above, the rates of non-fatal and fatal HF events were considerably lower in patients with HFmrEF and much more like those in HFpEF (at around half the rate of these events in patients with HFrEF). Again, this finding was very similar to what was seen in CHARM, the ESC Long-Term Registry, the Spanish cohort and in a recent analysis of beta-blocker trials (see below).
10 -13,15
Figure 1 Kaplan-Meier cumulative risk of composite outcome of cardiovascular death or heart failure hospitalisation according to left ventricular ejection fraction stratum. CI, confidence interval; HFmrEF, heart failure with mid-range ejection fraction; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; HR, hazard ratio.
Figure 2
Incidence rate of the composite outcome of cardiovascular death or heart failure hospitalisation according to left ventricular ejection fraction (LVEF) (spline analysis). Point estimates (the black solid line) and 95% confidence intervals (area between the dotted lines) for the rates of the composite outcome of cardiovascular death or heart failure hospitalisation according to LVEF. Rates are shown as per 100 patient-years. HFmrEF, heart failure with mid-range ejection fraction.
The unique aspect of the present study was the evaluation of the effect of digoxin according to LVEF category. Overall, in DIG, the predominant effect of digoxin was on hospital admission for HF and the composite of death from HF or hospitalisation for HF. 5 The size of the effect of digoxin treatment on this HF hospitalisation (and composites of this with either HF death or cardiovascular death)
. (TOPCAT) . 12, 13, 15, 16 Notably, none of the CHARM-Preserved, DIG or TOPCAT trials were positive for their primary endpoint but, interestingly, all three showed an overall significant reduction in HF hospitalisation (arguably the endpoint most 'sensitive' to the effect of a drug in HF). If we look at the effect of treatment on this endpoint in patients with HFmrEF in each of these three trials we see: CHARM (n = 1322 patients with HFmrEF), candesartan/placebo HR 0.72 (95% CI 0.55-0.95); TOPCAT (n = 520), spironolactone/placebo HR 0.76 (95% CI 0.46-1.27); and DIG (n = 1195), digoxin/placebo HR 0.80 (95% CI 0.63-1.03), all of which overlap. Only CHARM showed a nominally statistically significant effect of study drug. Where the three trials differ is in relation to cardiovascular death: here the HRs were 0.81 (95% CI 0.60-1.11) in CHARM, 0.69 (95% CI 0.43-1.12) in TOPCAT, and 1.24 (95% CI 0.94-1.64) in DIG, and hence the composite of cardiovascular death or HF hospitalisation: 0.76 (95% CI 0.61-0.96) in CHARM, 0.72 (95% CI 0.50-1.05) in TOPCAT (the primary also included a few cases of resuscitated cardiac arrest), and 0.96 (95% CI 0.79-1.17) in DIG. In another recent report, 575 patients with HFmrEF were included in a meta-analysis of beta-blocker trials. Unfortunately, HF hospitalisation was not reported as an endpoint but there was the suggestion that fatal outcomes might be reduced by beta-blockers in patients in this subgroup in sinus rhythm but the numbers were small and the estimate of treatment effect uncertain/unreliable. This benefit was not as apparent for the non-fatal outcome examined, which was cardiovascular hospitalisation (or the composite of cardiovascular death or cardiovascular hospitalisation).
The discrepancy between the studies may reflect the play of chance, given that all analyses were retrospective and had only moderate power, or it may represent true differences in responsiveness to distinct pharmacological interventions among the three HF phenotypes identified. Beta-blockers and angiotensin-converting enzyme inhibitors (and probably angiotensin receptor blockers) are beneficial in patients with coronary artery disease (and hypertension and diabetes), even in the absence of a reduced LVEF. No such suggestion has been made for digoxin in patients in sinus rhythm. Hence, beta-blockers and candesartan may truly have had a beneficial effect on cardiovascular mortality in patients with HFmrEF, whereas such a benefit might not have been anticipated with digoxin. Interpretation of the effect of spironolactone is more difficult. This drug does not seem to reduce mortality in patients with a normal or near-normal LVEF and whether there is a mortality benefit in patients with HFmrEF is uncertain because of the small size of this subgroup in TOPCAT and the resultant wide CI around the estimate of treatment-effect in these patients.
It is important to express a word of caution about all three of these studies. The retrospective nature and low power of each has been alluded to above. The beta-blocker analyses did not report tests of whether there was an interaction between treatment effect and LVEF (using LVEF as either a categorical or as a continuous variable) and in both CHARM and DIG, where such tests were done, they were not significant for the primary composite outcome, cardiovascular death or HF hospitalisation.
. Although such tests have low power, they suggest that we cannot definitively conclude that the effect of the treatments reviewed differ according to LVEF, even if the overall impression is that they do. This is a significant limitation of all three analyses discussed. The TOPCAT investigators could not do a similar analysis because the trial did not include patients with a LVEF <45%. That all patients in DIG were in sinus rhythm is both a weakness and a strength of this analysis-clearly many patients with HF do have atrial fibrillation but inclusion of those only in sinus rhythm removed the confounding influence of this arrhythmia when interpreting outcomes and effect of therapy. DIG is also an old dataset, collected at a time when neither beta-blockers or mineralocorticoid receptor antagonists were routinely used to treat patients with HF. Again, this is both a weakness and strength. While the effects of digoxin might be less in patients treated with contemporary therapy, lack of two of these therapies makes it easier to identify the effect of digoxin. Lack of these treatments also makes it less likely that the HFmrEF patients in DIG included many patients with 'recovered LVEF', i.e. the HFmrEF patients in DIG were likely a more homogeneous group than in more current cohorts. 2, 17 In summary, while patients with HFmrEF exhibited some similarities to those with HFrEF in terms of baseline characteristics, their rates of fatal and non-fatal HF events were substantially lower than in individuals with HFrEF. This and a smaller effect of digoxin on HF hospitalisation in patients with HFmrEF do not support the view that left ventricular systolic dysfunction is as important in this type of HF as in HFrEF.
